Breast Cancer
Trastuzumab deruxtecan ‘new gold standard’ in second line for breast cancer subset
SAN ANTONIO — Fam-trastuzumab deruxtecan-nxki significantly extended OS compared with ado-trastuzumab emtansine among previously treated patients with HER2-positive unresectable or metastatic breast cancer, according to study results.
Pausing endocrine therapy for pregnancy appears safe for women with breast cancer
SAN ANTONIO — Young women with early hormone receptor-positive breast cancer who temporarily stopped endocrine therapy to attempt pregnancy experienced similar short-term recurrence risk as those who did not stop, according to study results.
Longer CDK 4/6 inhibitor therapy enhances elacestrant benefit in metastatic breast cancer
SAN ANTONIO — Longer duration of cyclin-dependent kinase 4/6 inhibitor therapy in the metastatic setting appeared associated with extended PFS among elacestrant-treated patients with advanced breast cancer, according to study results.
Trastuzumab deruxtecan outperforms chemotherapy-based regimens for breast cancer subset
SAN ANTONIO — Fam-trastuzumab deruxtecan-nxki improved outcomes compared with capecitabine-based regimens as third-line treatment for certain patients with HER2-positive metastatic breast cancer, according to study findings.
Longer follow-up supports benefit of abemaciclib for high-risk breast cancer
SAN ANTONIO — The benefit of adding abemaciclib to adjuvant endocrine therapy for certain patients with high-risk breast cancer deepened with time, according to randomized phase 3 results presented at San Antonio Breast Cancer Symposium.
Washington University professor recognized for breast cancer prevention research
Adetunji T. Toriola, MD, PhD, MPH, will receive the AACR Outstanding Investigator Award for Breast Cancer Research at this year’s San Antonio Breast Cancer Symposium.
Fam-trastuzumab deruxtecan-nxki active in early HER2-low breast cancer
SAN ANTONIO — Fam-trastuzumab deruxtecan-nxki induced encouraging response rates among certain patients with early breast cancer, according to findings presented at San Antonio Breast Cancer Symposium.
UNC professor receives distinguished lectureship in breast cancer research
Charles M. Perou, PhD, received the 2022 AACR Distinguished Lectureship in Breast Cancer Research at this year’s San Antonio Breast Cancer Symposium.
Genomic assay may predict ovarian function suppression benefit in breast cancer subset
SAN ANTONIO — A genomic assay identified risk for distant recurrence among certain premenopausal women with hormone receptor-positive, early-stage breast cancer, according to study results presented at San Antonio Breast Cancer Symposium.
Ribociclib regimen may be superior to chemotherapy in advanced breast cancer
SAN ANTONIO — First-line ribociclib plus endocrine therapy appeared associated with longer PFS and fewer adverse events than combination chemotherapy among certain patients with advanced breast cancer, according to study results.